Korea Institute of Ocean Science & Technology

Korea Ocean Research and Development Institute

Sn Bioscience Inc.

Korea Ocean Research Institute

Se Jong Han

Joung Han Yim

Ha Ju Park

Tai Kyoung Kim

Il Chan Kim

Hyoung Seok Lee

Sung Jin Kim

Pil-Sung Kang

Il-Chan Kim

Jung Eun Kim

Heeyong Park

Dong-Gyu Jo

Doc Kyu Kim

Mi Ra Park

Dockyu Kim

Jun Hyuck Lee

Hyun Cheol Oh

Bhattarai Hari Datta

Cheolsoon Lee

Keun-Sik Kim

Yu-Kyung Park

Pyung Cheon Lee

Chul Soo Shin

Hari Datta Bhattarai

Sung Gu Lee

Hong Kum Lee

Min Ju Kim

Bon-Hun Koo

Ui Joung Youn

Su-Geun Yang

Babita Paudel-Bhattarai

Ju Mi Hong

Lee Don Hang

Seung Jin Kim

Keun Sik Kim

Hye Yeon Koh

Dong Gyu Jo

Yu-Kyeong Park

Kyung Hee Kim

Seul Ki Min

Pil Sung Kang

Jin Haeng Song

Kwon Joo Yeo

Suhkneung Pyo

Jong Han Yim

Ii Chan Kim

A lobamide compound according to an embodiment of the present disclosure is represented by Formula 1. The lobamide compound has excellent PTP-1B inhibitory activity that is far higher than that of conventional lobaric acid derivatives and which can be orally administered, and thus is very effective in the prevention or treatment of diabetes or obesity through oral administration.

Lobaric acid derivative having PTP-1B inhibitory activity, preparation method therefor and use thereof

The present invention can synthesize lobaric acid and four analogues thereof, which are five phenolic lichen metabolites isolated from an extract of the Antarctic lichenand selectively inhibit PTP1B, by a simple, economic and efficient chemical synthesis method.

Method for synthesis of lobaric acid and analog thereof

The present invention relates to an exopolysaccharide derived fromsp. strain CY01 (KCTC 12867BP) which is a novel strain living in the polar regions, and to a composition for cryoprotection of cells, which contains the exopolysaccharide. The exopolysaccharide of the present invention has an excellent ability to cryoprotect cells, and shows no cytotoxicity. Thus, the inventive exopolysaccharide can substitute for conventional cryoprotective agents that show cytotoxicity when used at high concentrations.

Cryoprotective agent containing exopolysaccharide fromsp. CY01

The present invention relates to a neurodegenerative disease treatment use, which is a novel use of Ramalin, and, more specifically, to a composition for preventing or treating neurodegenerative diseases, containing Ramalin, which has an inflammasome and BACE1 expression inhibitory activity. Ramalin according to the present invention has an effect of improving a cognitive ability by inhibiting the expression of an inflammatory factor, which contains an NLRP inflammasome protein, and BACE1, and is thus useful for preventing or treating memory disorder and neurodegenerative diseases.

Composition for preventing or treating neurodegenerative diseases, containing Ramalin

A cold-adapted protease derived fromPAMC 21717 or a recombinant cold-adapted protease obtained by expressing a gene encoding the cold-adapted protease inis described, and more particularly, a crystal of a protease exhibiting activity at low temperatures, a method for crystallizing the protease, a method for preparing the protease, a recombinant microorganism that expresses the protease, a method for preparing the recombinant microorganism, a method for preparing the recombinant protease and the use of the cold-adapted protease. The cold-adapted protease exhibits high activity at low temperatures, and securely maintains its enzymatic activity even in the presence of high pH, various metal ions and surfactants. Thus, it is useful in various industrial applications.

[object Object]

The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen, and more specifically to a pharmaceutical composition containing Ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and inhibits the expression of inducible nitric oxide synthase (iNOS) in the transcription stage to significantly inhibit the production of nitric oxide (NO) that is a key mediator of inflammatory responses. In addition, it inhibits the activation of the inflammatory mediator NF-&#x3ba;B, inhibits p38 MAPK, ERK1/2 and JNK signaling pathways, and inhibits the expression of the LPS receptor TLR4, suggesting that Ramalin has an excellent anti-inflammatory effect. Thus, the composition containing Ramalin can be effectively used to fundamentally treat or prevent inflammatory diseases or immune diseases and to relieve or alleviate the symptoms of the diseases.

Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin

There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived fromaccording to the present invention, to animal models, ramalin may remarkably suppress hepatic fibrosis and lower liver cirrhosis levels as compared to silymarin known as a liver cell protecting ingredient without cytotoxicity to normal liver cells, such that ramalin may be effectively used for preventing or treating hepatic fibrosis and liver cirrhosis.

Pharmaceutical composition for preventing or treating hepatic fibrosis and cirrhosis containing ramalin

Disclosed is a method of the synthesis of ramalin. It comprises reacting a glutamic acid derivative, which is prepared using alkylchloroformate, with a hydrazine salt compound, which is prepared from hydroxy aniline, whether protected or not. The synthesis method allows ramalin, excellent in antioxidant and anti-inflammatory activity, to be simply synthesized at stable yield even without use of a highly toxic solvent such as DMF. In addition, the method is cost competitive, and provides ramalin at high efficiency, thus enabling the mass production of ramalin.

Method for synthesizing ramalin and ramalin precursor by using glutamic acid derivative and hydroxy aniline or hydroxy aniline having protected hydroxy group

The present invention relates to a method for synthesizing ramalin, and more particularly to a method for synthesizing ramalin, which comprises allowing 2-hydrazinylphenol to react with L-glutamic acid having a protected carboxyl group at C-1 and a protected amino group at C-2, and a method for preventing decomposition of the ramalin. According to the present invention, ramalin having excellent antioxidant and anti-inflammatory activities can be synthesized in high yield, and thus can be produced in large amounts. In addition, ramalin can be stably maintained for a long period of time, and thus can be easily used for industrial purposes.

Method for preparing ramalin

The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.

Pharmaceutical and food compositions for preventing or treating diabetes or obesity

Growing community of inventors

Gyeonggi-do, South Korea

Se Jong Han